Last reviewed · How we verify
Val, Cel and Met XR High — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Val, Cel and Met XR High (Val, Cel and Met XR High) — ARKAY Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Val, Cel and Met XR High TARGET | Val, Cel and Met XR High | ARKAY Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Val, Cel and Met XR High CI watch — RSS
- Val, Cel and Met XR High CI watch — Atom
- Val, Cel and Met XR High CI watch — JSON
- Val, Cel and Met XR High alone — RSS
Cite this brief
Drug Landscape (2026). Val, Cel and Met XR High — Competitive Intelligence Brief. https://druglandscape.com/ci/val-cel-and-met-xr-high. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab